Schwab Fabienne Dominique, Bürki Nicole, Huang Dorothy Jane, Heinzelmann-Schwarz Viola, Schmid Seraina Margaretha, Vetter Marcus, Schötzau Andreas, Güth Uwe
Department of Gynecology and Obstetrics, University Hospital Basel (UHB), Spitalstrasse 21, 4031, Basel, Switzerland.
Fam Cancer. 2014 Mar;13(1):99-107. doi: 10.1007/s10689-013-9682-3.
This study evaluated the impact of family history (FH) on tumor detection, the patient's age and tumor size at diagnosis in breast cancer (BC). Furthermore, we investigated whether the impact of FH on these features was dependent on degree of relationship, number of relatives with a BC history, or the age of the affected relative at the time that her BC was diagnosed. Out of the entire cohort (n = 1,037), 244 patients (23.5%) had a positive FH; 159 (15.3%) had first-degree relatives affected with BC and 85 patients (8.2%) had second-degree affected relatives. Compared to women who had no BC-affected relatives, the tumors of women who had positive FH were more often found by radiological breast examination (RBE: 31.7%/27.2%, p = 0.008), and they were smaller (general tumor size: 21.8 mm/26.4 mm, p = 0.003; size of tumors found by breast self-examination (BSE): 26.1 mm/30.6 mm, p = 0.041). However, this positive effect of increased use of BC screening and smaller tumor sizes was only observed in patients whose first-degree relatives were affected (comparison with second-degree affected relatives: RBE: 43.8%/24.7%; odds ratio 2.38, p = 0.007; general tumor size: 19.3 mm/26.3 mm; mean difference (MD) -6.9, p = 0.025; tumor size found by BSE: 22.5 mm/31.0 mm; MD -8.5, p = 0.044). When more second-degree relatives or older relatives were diagnosed with BC, the tumors of these patients were similarly often detected by RBE (relationship: 24.7%/27.2%, p = 0.641; age: 33.7 %/27.2 %, p = 0.177) and had similar tumor sizes (general size: 26.3 mm/26.4 mm, p = 0.960; BSE: 31.0 mm/30.6 mm, p = 0.902) as those of women without a FH. Women with a positive FH generally use mammography screening more often and perceive changes in the breast earlier than women without such history. The increased awareness of BC risk decreases if the relationship is more distant.
本研究评估了家族史(FH)对乳腺癌(BC)肿瘤检测、患者诊断时年龄及肿瘤大小的影响。此外,我们还调查了FH对这些特征的影响是否取决于亲属关系程度、有BC病史的亲属数量或受影响亲属诊断BC时的年龄。在整个队列(n = 1037)中,244例患者(23.5%)有阳性家族史;159例(15.3%)有患BC的一级亲属,85例患者(8.2%)有患BC的二级亲属。与没有患BC亲属的女性相比,有阳性家族史女性的肿瘤更常通过乳腺放射检查(RBE)发现(RBE:31.7%/27.2%,p = 0.008),且肿瘤较小(总体肿瘤大小:21.8 mm/26.4 mm,p = 0.003;通过乳腺自我检查(BSE)发现的肿瘤大小:26.1 mm/30.6 mm,p = 0.041)。然而,BC筛查使用增加和肿瘤较小的这种积极作用仅在一级亲属受影响的患者中观察到(与二级亲属受影响的患者比较:RBE:43.8%/24.7%;优势比2.38,p = 0.007;总体肿瘤大小:19.3 mm/26.3 mm;平均差(MD)-6.9,p = 0.025;通过BSE发现的肿瘤大小:22.5 mm/31.0 mm;MD -8.5,p = 0.044)。当更多二级亲属或年龄较大的亲属被诊断为BC时,这些患者的肿瘤通过RBE检测到的频率类似(亲属关系:24.7%/27.2%,p = 0.641;年龄:33.7 %/27.2 %,p = 0.177),且肿瘤大小类似(总体大小:26.3 mm/26.4 mm,p = 0.960;BSE:31.0 mm/30.6 mm,p = 0.902),与没有家族史的女性相同。有阳性家族史的女性通常比没有此类病史的女性更频繁地进行乳腺钼靶筛查,并且更早察觉到乳房的变化。如果亲属关系更远,对BC风险的认识增加程度会降低。